2Owens D R,Dunseath G,Luzio S D. Postprandial beta-cell function following administration of repaglinide and glibenclamide in healthy subjects and Type 2 diabetes[J].{H}DIABETES,2000,(suppl1):A120.
21，Fuhlendorff J,Rorsman P,Kofod H et al.Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinet processes.Diabetes,1998;47(3):345
32，Owens DR.repaglinide-prandial glucose regulator:a new class of oral antidiabetic drugs.Diabet Med,1998;15suppl(4):S28
43，John R,White Jr,Pharm D.The pharmacological reduction of blood glucose in patients with type 2 diabetes melitus.Clinical Diabetes,1998;16:2
54 Polonsky KS,Sturis J,Bell CI.Seminars in Medicine of the Beth Israel Hospital,Boston.Non-insulin-dependent diabetes melitus-a genetically programmed failure of the beta cell to compensate for insulin resistance.N Engl J Med,1996;334(12):777
65，P J Lefebvre,Scheen AJ.The postprandial state risk of cardiovascular disease.Diabet Med,1998;15(Suppl 4):S63
76，Goldberg,Einhorn D,Lucas CP,et al.A randomized placebocontrolled trial of repaglinide in the teatment of type 2 diabetes.Diabetes Care,1998;21(11):1897
87，Landgraf R,Bilo HJ.A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas.1999;55(3):165
98，Wolffenbuttel BH,LandgrafR.A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes.Dutch and German repaglinide Study Group Diabetes Care,1999;22(3):463
